PAION AG

PAION AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS

PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults

PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing

​​​​​​​PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL

PAION AG: Gregor Siebert, buy

PAION AG issues statement on planned capital measure

PAION AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.01.2023 in Aachen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares

PAION AG announces change in Management Board

PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023

PAION AG enters partnership with Viatris and expands sales activities in Europe

PAION AG reports financial results for the first nine months of 2022

PAION AG raises EBITDA forecast for fiscal year 2022

PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN

PAION AG reports financial results for the first half-year 2022